Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Lancet Respir Med. 2021 Apr 14;9(10):1111–1120. doi: 10.1016/S2213-2600(21)00098-9

Figure 3.

Figure 3.

DS-Cav1 elicits robust and durable pre-F-binding antibodies that recognize the apex and side of the F protein.

Pre-F-binding IgG (Panel A) and IgA (Panel C) measured by ELISA and pre-F binding IgG in the presence of excess post-F (Panel B) which competes for post-F exclusive and dual-binding antibodies, demonstrating that binding antibodies are directed to the pre-F-exclusive and shared surfaces of pre-F and post-F. Panel E shows the level of pre-F-binding antibodies that compete with binding of the D25 antibody (apex-binding) and Panel F shows the level post-F-binding antibodies that competed with palivizumab antibody (side-binding). Panels G and H show levels of pre-F-binding IgG (Panel G) and IgA (Panel H) in mucosal samples. Statistical differences comparing weeks 0, 4, and 44 are determined by linear regression with no adjustment for multiple comparisons. Significance indicated as ***p<0·001.